Search Results

1 - 10 of 70 items :

  • "major depressive disorder" x
Clear All
Blood Cell Counts and Blood Cell Ratios as Non-Specific Major Depressive Disorder Biomarkers

disorder undergoing no pharmacological therapy. Neuropsychiatr Dis Treat. 2015;11:2253-8. 15. Demircan F, Gözel N, Kılınç F, Ulu R, Atmaca M. The Impact of Red Blood Cell Distribution Width and Neutrophil/Lymphocyte Ratio on the Diagnosis of Major Depressive Disorder. Neurol Ther. 2016;5(1):27-33. 16. Balta S, Demırkol S, Kucuk U. The platelet lymphocyte ratio may be useful inflammatory indicator in clinical practice. Hemodial Int. 2013;17(4):668-9. 17. Mazza MG, Lucchi S, Tringali AGM, Rossetti A, Botti ER, Clerici M. Neutrophil/lymphocyte ratio and

Open access
Association of SLC1A2 and SLC17A7 polymorphisms with major depressive disorder in a Thai population

Major depressive disorder (MDD) or major depression is a common psychiatric disorder in the general population [ 1 ]. According to the World Health Organization (WHO), MDD affects more than 350 million people worldwide. Moreover, the Burden of Disease (BOD) Research Program in 2013 revealed that a Thai population of around 1.5 million people suffered from depression [ 2 ]. Psychiatric disorders, especially MDD, have been strongly linked to suicide and suicide attempts [ 3 , 4 , 5 , 6 ]. A metaanalysis has found that approximately 90% of the people who

Open access
Family history as an important factor for stratifying participants in genetic studies of major depression

depressive disorder (MDD) is a field of study that has baffled many researchers; while it has shown great promise, it has actually yielded very few tangible results. Major depressive disorder has long been known to be moderately heritable. Twin studies have repeatedly shown the heritability of major depression to be about 37.0-38.0% [ 2 , 3 ]. Different approaches to studying the genetics of MDD have so far been consistent only in their inconsistency; linkage studies, candidate gene approaches, studies of gene-environment interaction, and more recent genome

Open access
Influence of demographic factors and serotonin transporter-linked polymorphic region (5-HTTLPR) variants on major depression in a northeastern Thai population

depression? J Affect Disord. 2003; 77: 273-5. 13. Nobile M, Cataldo MG, Giorda R, Battaglia M, Baschirotto C, Bellina M, et al. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatry. 2004; 56:292-5. 14. Hoefgen B, Schulze TG, Ohlraun S, von Widdern O, Höfels S, Gross M, et al. The power of sample size and homogenous sampling: association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry. 2005; 57

Open access
Augmentation Strategies for Patients with Major Depressive Disorder with an Inadequate Response to Antidepressant Monotherapy

References 1. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from Major Depressive Disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000-6. 2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40. 3. Bauer M, Bschor T, Pfennig A, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for

Open access
Association study of the tryptophan hydroxylase 1 gene with major depressive disorder in three ethnic groups of the Malaysian population

. Psychiatr Genet. 2005; 15:7-11. 12. Hong CJ, Tsai SJ, Wang YC. Association between tryptophan hydroxylase gene polymorphism (A218C) and schizophrenic disorders. Schizophr Res. 2001; 49: 59-63. 13. Tan EC, Chan AO, Tan CH, Mahendran R, Wang A, Chua HC. Case-control and linkage disequilibrium studies of the tryptophan hydroxylase gene polymorphisms and major depressive disorder. Psychiatr Genet. 2003; 13:151-4. 14. Bellivier F, Leboyer M, Courtet P, Buresi C, Beaufils B, Samolyk D, et al. Association between the tryptophan

Open access
Latvian Family Physicians’ Experience and Attitude in Diagnosing and Managing Depression

-vignette survey. PLoS ONE , 7 (12), e52429. Greenberg, P. E., Fournier, A.-A., Sisitsky, T., Pike, C. T., Kessler, R. C. (2015). The Economic burden of adults with major depressive disorder in the United States (2005 and 2010). J. Clin. Psychiatry, 76 (2), 155–162. Hall, J. A., Irish, J. T., Roter, D. L., Ehrlich, C. M., Miller, L. H. (1994). Gender in medical encounters: An analysis of physician and patient communication in a primary care setting. Health Psychology , 13 (5), 384–392. Honigfeld, L., Macary, S. J., Grasso, D. J. (2017). A clinical

Open access
Review of a New Multimodal Antidepressant Vortioxetine

REFERENCES 1. Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014; 10: 1297-1307. 2. Andrade L, Caraveo-Anduaga JJ, Berglund P et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res. 2003; 12 (3): 165. 3. Farsky I, Smetanka A, Dubinska S. Spirituality of patients with selected psychiatric disorders

Open access
Increased Cortisol Levels in Depression: A Comparative Study Evaluating the Correlation of Hypercortisolemia with Prosocial Coping Mechanisms

volume in MDD. European Journal of Psychotraumatology. 2012;3(1). 12. Dedovic KEV, Duchesne A, Lue S, et al. Cortisol awakening response and hippocampal volume: vulnerability for major depressive disorder? Biol Psychiatry. 2010;68(9):847-53. 13. Holsboer F. Redesigning antidepressant drug discovery. Dialogues Clin Neurosci. 2014;16(1):5-7. 14. Mossner R, Mikova O, Koutsilieri E, et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry. 2007

Open access
Efficacy of vortioxetine monotherapy compared with combined therapy vortioxetine and olanzapine in the treatment of major depression – first results

References [1] Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. 2014;10:1297–1307. [2] Farsky I, Smetanka A, Dubinska S. Spiritualita pacientov s vybranymi psychiatrickymi diagnozami. Osetrovatelstvi a porodni asistence. 2012;3(3):433–441. [3] Nemeroff CB. Prevalence and management of treatment resistant depression. J Clin Psychiatry. 2007;68(Suppl 8):17–25. [4] Serreti A, Chiesa A. Treatment-emergent sexual dysfunction

Open access